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Abstract
Arteriovenous fistulae (AVF) are the most common access created for
hemodialysis, but up to 60% do not sustain dialysis within a year, suggesting a need to
improve AVF maturation and patency. In a mouse AVF model, Akt1 regulates fistula wall
thickness and diameter. We hypothesized that inhibition of the Akt1-mTORC1 axis alters
venous remodeling to improve AVF patency. Daily intraperitoneal injections of
rapamycin reduced AVF wall thickness with no change in diameter. Rapamycin
decreased smooth muscle cell (SMC) and macrophage proliferation; rapamycin also
reduced both M1 and M2 type macrophages. AVF in mice treated with rapamycin had
reduced Akt1 and mTORC1 but not mTORC2 phosphorylation. Depletion of
macrophages with clodronate-containing liposomes was also associated with reduced
AVF wall thickness and both M1- and M2-type macrophages; however, AVF patency was
reduced. Rapamycin was associated with improved long-term patency, enhanced early
AVF remodeling and sustained reduction of SMC proliferation. These results suggest
that rapamycin improves AVF patency by reducing early inflammation and wall
thickening while attenuating the Akt1-mTORC1 signaling pathway in SMC and
macrophages. Macrophages are associated with AVF wall thickening and M2-type
macrophages may play a mechanistic role in AVF maturation. Rapamycin is a potential
translational strategy to improve AVF patency.
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1. Introduction
1.1 Poor Clinical Outcomes in Arteriovenous Fistulae Utilization
Veins are frequently exposed to arterial environment by surgeons when creating
arteriovenous fistulae (AVF) for hemodialysis access in end-stage renal disease (ESRD).
With over half a million people affected by ESRD in the United States and a mortality of
approximately 88,000 people each year, the incidence of ESRD requiring therapy is over
100,000 new cases a year.1 An AVF, which joins a vein directly to the artery is the
preferred mode of hemodialysis access with demonstrated superior long-term results
compared to prosthetic grafts and catheter access.2 Despite the known superiority, AVF
are still far from perfect; they must mature, e.g. dilate, thicken and increase flow prior
to use. However AVF can fail to mature in ~30% of cases3 and even if matured correctly,
primary AVF failure occurs in ~35-40% in just the first year.4 These poor clinical results of
AVF reflect our imperfect understanding of how the vein adapts to the arterial
environment and clearly shows that our knowledge gap creates an unmet medical need
for novel approaches to enhance venous adaptation.4-6 The Society of Vascular Surgery
recently published enhancing AVF maturation and durability as one of its highest and
most critical clinical research priorities.7

1.2. Mechanisms of Fistula Maturation and Failure
Following AVF creation, the vein is exposed to a high flow and shear stress, low
pressure arterial environment, leading to “maturation” of both the arterial inflow and
venous outflow segments – a process necessary to sustain the high flow rates required
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for a successful dialysis session. Adaptation of the vein to the increased flow and shear
stress requires dilation and outward remodeling of the venous wall. This process is
accomplished by a delicate balance of extracellular matrix (ECM) remodeling,
inflammation, growth factor secretion, and cell adhesion molecule upregulation in all
three layers of the venous wall.8-11
During fistula maturation, the ECM of the venous limb exhibits changes as an
adaptive response to the “arterialized” environment.12 These changes can be
categorized in to three temporal phases; early phase (breakdown), transition phase
(reorganize) and late phase (rebuild). The early phase is characterized by an increased
ratio of matrix metalloproteinase (MMP) to tissue inhibitor of metalloproteinase (TIMP),
which results in degradation of collagen and elastin scaffolds, allowing for easier cell
migration during the transition and late phases. Reorganization of scaffolds and
rebuilding of the ECM with larger non-collagenous and glycoproteins such as fibronectin
occur after the breakdown phase to allow for complete fistula maturation.13
While ECM degradation is regulated by MMP, its deposition is modulated by
transforming growth factor-β (TGF-β).14 Diverse cell types in the venous wall, such as
endothelial cells (EC), smooth muscle cells (SMC), and inflammatory cells produce TGF-β
and its expression is upregulated during both early and late phases of AVF maturation.
While local inflammation of the vessel wall is necessary for successful fistula maturation,
elevated systemic inflammatory markers predict fistula failure.9,15 Locally, macrophages
and T-cells play an important role in AVF maturation, with maturation being promoted
by M2 type macrophage and a lack of T cell activity resulting in AVF maturation failure.
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Furthermore, presence of CD4+ T-cells in mature AVF coincides with the presence of
macrophages, and the absence of mature T-cells results in reduced macrophage
infiltration.16,17 Systemic inflammation has been shown to negatively correlate with AVF
maturation, and higher levels of C-relative protein increase the risk of AVF failure.
Further, prednisolone, a drug with anti-inflammatory properties, enhances venous
outward remodeling.18 Use of paclitaxel, a chemotherapeutic and immunosuppressive
agent, during drug-coated balloon angioplasty leads to inhibition of neointimal
hyperplasia (NIH) and has shown encouraging 6-month patency rates.19-21 However,
increased infection rates have become a major concern for paclitaxel use in AVF.22
Successful AVF maturation relies on venous wall thickening and outward
remodeling in order to support flow rates required for successful hemodialysis. AVF
failure occurs via 2 distinct mechanisms; early fistula failure occurs secondary to lack of
outward remodeling or wall thickening, while late failure occurs as a result of
development of NIH and impaired outward remodeling in a previously functional
conduit.23 Unfortunately primary maturation and patency rates of AVF remain low. Up
to 60% of AVF fail to mature by 5 months after creation, and literature shows primary
patency rates of 60% at 1 year and 51% at 2 years, with secondary patency rates of 71%
at 1 year and 64% at 2 years.5,24,25 Factors such as diabetes mellitus, peripheral vascular
disease, congestive heart failure, and older age are poor prognostic factors for
successful AVF placement.26 Furthermore, studies have demonstrated prolonged
maturation time, decreased patency, and increased early thrombosis of AVF in female
patients, differences not accounted for by smaller vein size in females.27-29
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1.3. Akt1 signaling in AVF maturation
Erythropoietin-producing hepatocellular carcinoma (Eph) receptors with ephrins,
their ligands, play an essential role in vascular development and determine arterial
versus venous identities.30,31 Eph receptor activation leads to downstream signaling via
the PI3K-Akt pathway, resulting in cell migration and proliferation, functions critical for
venous remodeling.32,33 Specifically, Eph-B4 modulates adaptation and AVF maturation
with distinct patterns of altered vessel identity.34-36 During successful AVF maturation,
the venous limb gains expression of ephrin-B2 and has increased Eph-B4 expression,
relative to control veins, suggesting acquisition of dual arterial-venous identity.12
Although the route of ephrin-B2 signaling during AVF maturation remains unknown, it
must be membrane bound and circulating endothelial progenitor cells can be a source.37
In vivo, Eph-B4 activation attenuates Akt1 phosphorylation leading to reduced
venous wall thickening, reduced outward remodeling and improved long-term patency
rates. This was corroborated with constitutively active-Akt1 studies which lead to
increased venous wall thickening and dominant negative-Akt1 studies which lead to
reduced outward remodeling.36 Therefore, it is proposed that Eph-B4 can regulate
venous remodeling via an Akt1-mediated mechanism.36 Moreover, Akt1 expression is
upregulated during venous remodeling, both during vein graft adaptation,38 as well as
during AVF maturation, a consistent response to two different hemodynamic
environments;36 during AVF maturation, Akt1 regulates both venous wall thickening as
well as dilation.36 Mammalian target of rapamycin (mTOR) is a key regulatory protein
that integrates signals from several pathways including the Akt1 pathway to modulate
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inflammation and coordinate cell growth and proliferation, all of which occur during
venous remodeling.39 Rapamycin, an mTOR inhibitor, is currently used for human
therapy to prevent NIH by reducing proliferation and migration of smooth muscle
cells.40,41
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2. Statement of Purpose and Aims
2.1. Statement of Purpose
Since rapamycin inhibits Akt1 signaling, and Akt1 mediates venous remodeling,
we hypothesize that inhibition of the Akt1-mTORC1 axis in macrophages with rapamycin
alters venous adaptive remodeling in AVF.

2.2. Aims
Specific Aim I: Determine the effects of rapamycin as a downstream inhibitor of Akt1
signaling on AVF patency
Specific Aim II: Determine the effects of macrophage depletion on AVF maturation
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3. Methods
3.1. Study Approval
All animal experiments were performed in strict compliance with federal
guidelines and with approval from the Yale University IACUC.

3.2. Infrarenal aorto-caval fistula
Mice used for this study were wild type C57BL6/J. Mice were 9–12 weeks of age
when the infrarenal aorto-caval fistulae were created as previously described;42,43 only
male mice were studied since female sex is the only predictor of non-maturation of
human AVF in some studies.44 Briefly, AVF were created by needle puncture from the
aorta into the inferior vena cava (IVC) using a 25G needle. Visualization of pulsatile
arterial blood flow in the IVC was assessed as a technically successful creation of AVF.
Following surgery, all animals were monitored daily and evaluated weekly by a
veterinarian for changes in health status.

3.3. Confirmation of fistula patency and measurement of fistula dilation
Doppler ultrasound (40 MHz; Vevo770 High Resolution Imaging System; Visual
Sonics Inc., Toronto, Ontario, Canada) was used to confirm the patency of the AVF and
to measure the diameter of the vessels as previously described.42,43 Doppler ultrasound
was performed prior to operation (day 0 values) and serially post-operatively. Increased
end-diastolic flow through the aorta and a high velocity pulsatile flow within the IVC
confirmed the presence of an AVF during post-operative studies. Patency was again
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confirmed at time of AVF harvest by direct visualization of pulsatile arterial blood flow
into the IVC, and in all cases correlated with the ultrasound findings.

3.4. Histology
After euthanasia, the circulatory system was flushed under pressure with PBS
followed by 10% formalin and the AVF was harvested en bloc. The tissue was then
embedded in paraffin and cut in 5 μm cross sections. Hematoxylin and eosin staining
was performed for all samples. Elastin Van Gieson (EVG) staining was used to measure
intima-media thickness in 5 μm cross sections of the IVC using sections obtained 100200 µm cranial to the fistula. Four equidistant points around the IVC and opposite the
aortic wall were averaged in each cross section to obtain the mean AVF outer wall
thickness. Additional unstained cross sections in this same region were used for
immunofluorescence microscopy.

3.5. Immunohistochemistry and Immunofluorescence
Tissue sections were de-paraffined using xylene and a graded series of alcohols.
Sections were heated in citric acid buffer (pH 6.0) at 100 °C for 10 min for antigen
retrieval. The sections were blocked with 5% bovine serum albumin PBS containing
0.05% Triton X-100 (T-PBS) for 1h at room temperature prior to incubation overnight at
4 °C with the primary antibodies diluted in T-PBS. All the primary antibodies have been
listed in the Table 1. Sections were then treated with secondary antibodies at room
temperature for 1h using goat anti-rabbit Alexa Fluor 488 (Life Technologies), donkey
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anti-goat Alexa-Fluor-488 (Life Technologies), or donkey anti-rabbit Alexa-Fluor-568 (Life
Technologies). Sections were stained with Slow Fade® Gold Antifade Mount with DAPI
(Life Technologies) and coverslip was applied. Digital fluorescence images were
captured and intensity of immunoreactive signal was measured using Image J software
(NIH, Bethesda, Maryland). Intensity of the merge signal was determined by applying a
color threshold selective for the appropriate signal.
Table 1. List of Antibodies
Target antigen

Vendor or Source

Catalog #

Cleaved caspase-3

Cell Signaling

9664

proliferating cell nuclear antigen

Dako

M0879

Collagen I

Novus Biologicals

NB600-408

Collagen III

Novus Biologicals

NB600-594

fibronectin

Abcam

ab2413

CD68

Bio-Rad

MCA1957

iNOS

Cell Signaling

2977S

interleukin-10

Abcam

ab9969

TNFa

Abcam

ab9635

CD206

Bio-Rad

MCA2235T

VECAM1

Abcam

ab134047

ICAM1

R&D Systems

AF796-SP

Phospho-Akt1

Cell Signaling

9018
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Akt1

Cell Signaling

2967

Phospho-mTOR (Ser2481)

Cell Signaling

2974

Phospho-mTOR (Ser2448)

Cell Signaling

2971

phospho-4EBP1

Cell Signaling

2855

4EBP1

Cell Signaling

9452

phospho-70SK1

Abcam

17464

70S6K1

Cell Signaling

9202

phospho-PKCα

Abcam

23513

PKCα

Cell Signaling

2056

Phospho-SGK1

Thermo Fischer

44-1260G

SGK1

Abcam

59337

Alpha-actin

Dako

M0851

GAPDH

Cell Signaling

2118

3.6. Western Blot
The venous limb of the AVF was harvested and treated with RIPA lysis buffer
containing protease inhibitors. Equal amounts of protein were loaded and run in SDSPAGE followed by Western blot analysis. Protein expression was probed with the
antibodies listed in Table 1.
Membranes were developed using Western Lightning Plus ECL reagent
(PerkinElmer). Membranes were stripped with Restore Western Blot Stripping Buffer
(Pierce Biotechnology) and then re-probed. Band densitometry was performed using
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Image J and was normalized to GAPDH or the ratio of phosphorylated to total protein
was calculated.

3.7. Rapamycin and clodronate treatment
Intraperitoneal (IP) injections of rapamycin (100 µg; #553212, Sigma Aldrich)
were delivered every 24h beginning on the day of operation and continued throughout
the study period. In mice treated with adenovirus containing constitutively active Akt1,
250 µg of rapamycin was used. The control group received an equal volume injection of
vehicle (DMSO) as control. In the adventitial delivery group, pluronic gel was used to
deliver 100 µg of rapamycin to the adventitia of the venous AVF wall of at the time of
surgery.
Intraperitoneal injections of clodronate-containing liposomes (0.5 mg/Kg; CLD8909, Encapsula Nano Sciences) were delivered every 72hr beginning on postoperative
day 1 and continued throughout the study period. The control group received an equal
volume injection of vehicle (PBS). Intraperitoneal injections of 20 µg Ephrin-B2/Fc (R&D)
were delivered 24h prior to AVF creation and every 48h thereafter. Control mice
received an equal volume injection of vehicle (PBS) as control.

3.8. Adenovirus treatment
Infrarenal aorto-caval AVF were created as described above. After unclamping
and confirming fistula flow, 1·106 copies of commercially available vectors (Vector
Biolabs, Malvern, PA) containing either constitutively active Akt1 adenovirus (Myr-HA-

12
Akt1), or a control virus (WT-HA-Akt1) were applied to the AVF adventitial surface in a
25% w/v pluronic gel. The HA reporter tag in these vectors were used for
immunofluorescent confirmation of virus delivery. After visual confirmation that the
pluronic gel mixture had solidified, the abdomen was closed as described above.

3.9. Statistics
Data are represented as mean value ±SEM. All data were analyzed using Prism 8
software (GraphPad Software, Inc., La Jolla, CA). The Shapiro-Wilk test was performed to
analyze normality and the F test was performed to evaluate homogeneity of variances.
For two-group comparisons with normally distributed data, the unpaired Student’s t test
was used for data with equal variances among groups and the unpaired Student’s t test
with Welch correction was used for data with unequal variances. For multiple group
comparisons with normally distributed data, the one-way ANOVA followed by the
Sidak’s post-hoc test was used. Patency outcomes were analyzed with the use of
Kaplan–Meier curves to display the distribution of occlusion events detected over time.
P values < 0.05 were considered significant.
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4. RESULTS
4.1. Reduced AVF wall thickness, extracellular matrix deposition, SMC and
macrophages with rapamycin
To determine the effects of mTOR signaling during venous remodeling such as
occurs during AVF maturation, we used a mouse model of AVF that recapitulates human
AVF maturation.43 Aortocaval fistulae were created as previously described and
afterwards mice received daily intraperitoneal (IP) injections of rapamycin (100 µg) or
vehicle alone; in mice treated with rapamycin, rapamycin was detectable in serum
without any systemic signs of immunosuppression or toxicity (Supplemental Figure 1A).
The IVC of sham-operated and fistula of control-treated and rapamycin-treated mice
were harvested and analyzed on postoperative days 3, 7 and 21 (Supplemental Figure
1B). Compared to sham-operated mice, control AVF showed wall thickening that was
reduced in AVF treated with rapamycin (Fig. 1A and B; Supplemental Figure 1C and D);
however, there was no significant difference in the dilation of the IVC (Fig. 1C) or the
aorta (Supplemental Figure 1E), as well as immunoreactivity of p-eNOS-ICAM dualpositive cells (Fig. 1D; Supplemental Figure 1F), between rapamycin-treated and control
groups. Since rapamycin treatment reduced AVF wall thickening, we determined the
effect of rapamycin on components of the AVF wall including several extracellular
matrix (ECM) proteins as well as endothelial cells (EC),45,46 smooth muscle cells
(SMC),36,47,48 and macrophages.47,49,50 There was reduced immunoreactivity
of collagen I, collagen III, and fibronectin in the AVF wall of rapamycin-treated mice,
compared to control mice (Fig. 1E and F; Supplemental Figure 1G). There were fewer
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Figure 1. Reduced AVF wall thickness, extracellular matrix deposition, SMC and macrophages with
rapamycin. (A) Representative photomicrographs showing AVF wall thickness in mice treated with
rapamycin vs. control (day 21). Scale bar, 25 µm. L, lumen. (B) Bar graph showing AVF wall thickness in
mice treated with rapamycin vs. control; p<0.0001 (ANOVA); *, p<0.0001 (Sidak’s post hoc); n=5-9. (C)
Line graph showing relative AVF diameter in mice treated with rapamycin vs. control; normalized to day 0;
p=0.534 (ANOVA); n=6. (D) Bar graphs showing quantification of dual IF after control or rapamycin
treatment at days 3, 7, 21, normalized to sham. p-eNOS-ICAM1: p<0.1383 (ANOVA); n=4-6. (E)
Photomicrographs showing representative of extracellular matrix immunoreactive signals in control or
rapamycin treated groups (day 7). Collagen I or III (red) and fibronectin (green). (F) Bar graphs showing
quantification of IF, normalized to sham. Collagen I: p<0.0001 (ANOVA); *, p=0.0006, day 7; *, p<0.0001,
day 21 (post hoc); n=4. Collagen III: p<0.0001 (ANOVA); *, p=0.0122, day 7; *, p<0.0001, day 21 (post
hoc); n=4. Fibronectin: p<0.0001 (ANOVA); *, p<0.0001 (post hoc); n=5. (G) Bar graphs showing number of
ICAM-1+, α-actin+ or CD68+ cells in AVF after control or rapamycin treatment. ICAM-1: p=0.7455 (ANOVA).
n=5. α-actin: p<0.0001 (ANOVA). *, p<0.0002, day 3; *, p<0.0001, day 7; *, p<0.0001, day 21 (post hoc);
n=5. CD68: p<0.0001 (ANOVA). *, p<0.0001, days 3 and 7; *, p=0.0463, day 21 (post hoc); n=5. (H)
Photomicrographs showing representative IF of PCNA (red) merged with ICAM, α-actin or CD68 (green),
and DAPI (blue) in AVF of control vs rapamycin treated mice (day 7); L, lumen; scale bar, 25 μm. White
arrowheads indicate merged signal. (I) Bar graphs showing percentage of dual positive cells. PCNA-ICAM:
p=0.4137 (ANOVA). n=4-5. PCNA-α-actin: p<0.0001 (ANOVA). *, p<0.0001, day 3; *, p=0.0011, day 7 (post
hoc); n=4-5. PCNA-CD68: p<0.0001 (ANOVA). *, p=0.0002, day 3; *, p=0.0023, day 7 (post hoc); n=4-5. (J)
Photomicrographs showing representative IF of cleaved caspase-3 (red) merged with ICAM, α-actin or
CD68 (green), and DAPI (blue) in AVF of control or rapamycin treated mice (day 7); L, lumen; scale bar,
25 μm. White arrowheads indicate merged signal. (K) Bar graphs showing percentage of dual positive
cells. Cleaved caspase-3-ICAM: p=0.08777 (ANOVA); n=4-5. Middle graph, cleaved caspase-3-α-actin:
p=0.1266 (ANOVA). n=4-5. Right graph, cleaved caspase-3-CD68: p=0.2663 (ANOVA); n=4-5.
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numbers of α-actin-positive cells and CD68-positive cells, without any change in
numbers of intercellular adhesion molecule-1 (ICAM-1)-positive cells, in the AVF of
rapamycin-treated mice compared to control mice, consistent with reduced numbers of
SMC and macrophages but not EC with rapamycin treatment (Fig. 1G; Supplemental
Figure 1H). The reduced number of α-actin-positive cells and CD68-positive cells with
rapamycin treatment was associated with reduced PCNA immunoreactivity (Fig. 1H and
I; Supplemental Figure 1I); however, there was no increase in cleaved caspase-3
immunoreactivity with rapamycin treatment (Fig. 1J and K; Supplemental Figure 1J).
These data suggest that the reduced AVF wall thickening with rapamycin treatment is
associated with less SMC and macrophage proliferation.

4.2. Reduced M1- and M2-type macrophages with rapamycin
Since rapamycin treatment was associated with reduced macrophage
proliferation (Fig. 1), we determined whether rapamycin had differential effects on
macrophage subpopulations. The wall of the rapamycin-treated AVF showed decreased
iNOS and TNF-a immunoreactive protein, markers of M1-type macrophages, as well as
decreased IL-10 and CD206 protein, markers of M2-type macrophages, at both days 3
and 7 (Fig. 2A and B). Rapamycin-treated AVF also showed reduced immunoreactivity of
CD68-iNOS dual-positive cells as well as CD68-TNF-a dual-positive cells in the adventitia
(Fig. 2C and D; Supplemental Figure 2A); there was also reduced immunoreactivity of
CD68-IL-10 dual-positive cells as well as CD68-CD206 dual-positive cells in the adventitia,
at both days 3 and 7 (Fig. 2E and F; Supplemental Figure 2B). Rapamycin treatment was
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Figure 2. Reduced M1- and M2-type macrophages with rapamycin. (A) Representative Western blot
showing iNOS, TNF-α, IL-10 and CD206 protein expression levels in AVF treated with rapamycin or
control (day 3 and 7). (B) Graphs showing densitometry measurements of iNOS, TNF-α, IL-10 and
CD206 expression in the AVF after control or rapamycin treatment, normalized to GAPDH. iNOS:
p=0.0011 (ANOVA). *, p=0.0241, day 3; *, p=0.0054, day 7 (post hoc); n= 2-3. TNF-α: *p=0.0020
(ANOVA). *, p=0.0223, day 3; *, p=0.0250, day 7 (post hoc); n= 2-3. IL-10: *p<0.0001 (ANOVA). *,
p=0.0011, day 3; *, p=0.0006, day 7 (post hoc); n= 2-3. CD206: p=0.0013 (ANOVA). *, p=0.0126, day
3; *, p=0.0200, day 7 (post hoc); n= 2-3. (C) Photomicrographs showing representative dual IF for
CD68 (red) and iNOS (green, top row) or CD68 (red) and TNF-a (green, bottom row) in AVF after
control or rapamycin treatment (day 7). Scale bar, 25 μm. L, lumen. (D) Bar graphs showing
quantification of dual IF after control or rapamycin treatment. Left graph, iNOS-CD68: p<0.0001
(ANOVA). *, p=0.0006, day 3; *, p=0.0004, day 7; *, p=0.0073, day 21 (post hoc); n=5. Right graph,
TNF-a-CD68: p<0.0001 (ANOVA). *, p<0.0001, day 3; *, p<0.0001, day 7 (post hoc); n=5. (E)
Photomicrographs showing representative dual IF for CD68 (red) and IL-10 (green, top row) and CD68
(red) and CD206 (green, bottom row) in control or rapamycin treated AVF (day 7). (F) Bar graphs
showing quantification of dual IF after control or rapamycin treatment (day 7). Left graph, IL-10CD68: p<0.0001 (ANOVA). *, p<0.0001, day 3; *, p<0.0001, day 7 (post hoc); n=5. CD206-CD68:
p<0.0001 (ANOVA). *, p<0.0001, day 3; *, p<0.0001, day 7 (post hoc); n=5. (G) Photomicrograph of
representative of CD45+ cells in control or rapamycin treated mice AVF (day 7). (H) Bar graph
showing number of CD45 immunoreactive cells in AVF after control vs rapamycin treatment;
p<0.0001 (ANOVA); *, p<0.0001, day 3; *, p=0.0020, day 7; *, p=0.2110, day 21 (post hoc); n=5. (I)
Representative photomicrographs showing VCAM-1 (top row) and ICAM-1 (bottom row) IF in AVF
after control or rapamycin treatment (day 7). (J) Bar graphs showing relative quantification of VCAM1 and ICAM-1 intensity in AVF, normalized to sham vessels. VCAM-1: p=0.3162 (ANOVA); n=6. ICAM1: p=0.9280 (ANOVA); n=4-6. Data represent mean ± SEM.
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also associated with fewer number of leukocyte common antigen (CD45)
immunoreactive cells (Fig. 2G and H; Supplemental Figure 2C), but there was no
difference in immunoreactivity of vascular cell adhesion molecule-1 (VCAM-1) or ICAM-1
(Fig. 2I and J; Supplemental Fig. 2D). These data suggest that rapamycin is associated
with reduced immunoreactivity of both M1-type and M2-type macrophages as well as
fewer leukocytes during AVF remodeling.

4.3. Reduced Akt1 and mTORC1 but not mTORC2 phosphorylation with rapamycin
Since mTOR binds to either the Raptor regulatory subunit to form mTORC1, a
downstream target of Akt1,51 or to the Rictor regulatory subunit to form mTORC2,52 an
upstream regulator of Akt1,39 we next determined whether rapamycin altered the
phosphorylation of either of these complexes during AVF remodeling. Rapamycin was
associated with reduced numbers of p-Akt1 immunoreactive cells (days 7 and 21) and pmTORC1 immunoreactive cells (days 3 and 7), but there was no difference in the
numbers of p-mTORC2 immunoreactive cells (Fig. 3A and B; Supplemental Figure 3A).
Similarly, mice treated with rapamycin had decreased expression of phosphorylated
Akt1 and phosphorylated mTORC1, with no significant change in expression of
phosphorylated mTORC2, in the AVF wall (days 3-21; Fig. 3C and D). Reduced Akt1 and
mTORC1 phosphorylation with rapamycin was similarly reduced in both p-Akt1-α-actin
dual-positive cells as well as p-mTORC1-α-actin dual-positive cells (Fig. 3E and F;
Supplemental Figure 3D); immunoreactivity was also reduced with rapamycin
treatment in p-Akt1-CD68 dual-positive cells as well as p-mTORC1-CD68 dual-positive
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Figure 3. Reduced Akt1 and mTORC1 but not mTORC2 phosphorylation with rapamycin. (A)
Photomicrographs showing representative IF of p-Akt1+ (top, red), p-mTORC1+ (middle, red) and
p-mTORC2+ (bottom, red) cells in control or rapamycin treated mice AVF (day 7). Scale bar,
25μm. L, lumen. (B) Bar graphs showing number of p-Akt1+, p-mTORC1+ and p-mTORC2 + cells in
AVF after rapamycin or control treatment. p-Akt-1: *, p<0.0001 (ANOVA); *, p<0.0001, day 7; *,
p =0.0105, day 21 (post hoc); n=4-5. p-mTORC1: p<0.0001 (ANOVA); *, p<0.0001, day 3; *,
p<0.0001, day 7 (post hoc); n=4-5. p-mTORC2: p=0.2870 (ANOVA); n=4-5. (C) Representative
Western blot showing Akt1, mTORC1, mTORC2 phosphorylation level after control vs rapamycin
treatment. (D) Graphs showing densitometry measurement of Akt1, mTORC1 and mTORC2
phosphorylation. p-Akt1: tAkt1, p=0.0002 (ANOVA); *, p=0.0110, day 7; *, p=0.0359, day 21
(post hoc); n=3. p-mTORC1: tmTORC1, p=0.0004 (ANOVA); *, p=0.0157, day 3; *, p=0.0192, day
7; *, p=0.0366, day 21 (post hoc); n=3. p-mTORC2: tmTORC2: P=0.9893 (ANOVA); n = 3. (E)
Photomicrographs showing representative IF of dually-positive α-actin (green) and p-Akt1 (red,
first row) or p-mTORC1 (red, second row) in AVF after control or rapamycin treatment (day 7). (F)
Bar graphs showing quantification of dual IF after control vs rapamycin treatment. P-Akt1-αactin: p<0.0001 (ANOVA); *, p=0.0002, day 7; *, p=0.0017, day 21 (post hoc); n=4-5. p-mTORC1α-actin: p<0.0001 (ANOVA); *, p=0.0136, day 7; *, p<0.0001, day 21 (post hoc); n=4. (G)
Photomicrographs showing representative dual IF for CD68 (green) and p-Akt1 (red, top row) or
p-mTORC1 (red, bottom row) in AVF after control or rapamycin treatment (day 7). (H) Bar graphs
showing quantification of dual IF after control vs rapamycin treatment. p-Akt1-CD68: p<0.0001
(ANOVA); *, p=0.0013, day 7; *, p=0.0183, day 21 (post hoc); n=4-5. p-mTORC1-CD68: p<0.0001
(ANOVA); *, p<0.0001, day 3; *, p<0.0001, day 7 (post hoc); n=4-5. Data represent mean ± SEM.
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cells (Fig. 3G and H; Supplemental Figure 3E). However, there was no significant
difference in immunoreactivity of p-Akt1-ICAM dual-positive cells or p-mTORC1-ICAM
dual-positive cells with rapamycin treatment (Supplemental Figure 3B and C). These
data suggest that rapamycin is associated with less Akt1-mTORC1 signaling, in both SMC
and macrophages, during AVF remodeling.
Since these data show that rapamycin reduces mTORC1, but not mTORC2,
phosphorylation (Fig. 3), we evaluated the phosphorylation of P70S6K and 4EBP1,
downstream targets of mTORC1.53 There were significantly fewer number of cells that
were immunoreactive for p-P70S6K1 or p-4EBP1 in the AVF of mice treated with
rapamycin compared to control (Fig. 4A; Supplemental Figure 4A); however, there was
no effect on the number of cells that were immunoreactive for p-PKCα or p-SGK1,
downstream targets of mTORC2 (Fig. 4B; Supplemental Figure 4B). Similarly, AVF
treated with rapamycin had significantly decreased expression of phosphorylated
P70S6K and 4EBP1 (Fig. 4C and D), but no significant change in expression of
phosphorylated PKCα or SGK1 (Fig. 4E; Supplemental Figure 4C). These results suggest
that rapamycin regulates the mTORC1, but not mTORC2 pathway, during venous
remodeling.
The AVF of mice treated with rapamycin similarly showed decreased
immunoreactivity of p-P70S6K-α-actin dual-positive cells and p-4EBP1-α-actin dualpositive cells (Fig. 4F and G; Supplemental Figure 4D); rapamycin-treated AVF also
showed decreased immunoreactivity of p-P70S6K-CD68 dual-positive cells and p-4EBP1CD68 dual-positive cells (Fig. 4H and I; Supplemental Figure 4E). However, there was no
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Figure 4. Reduced p70S6K1 and 4EBP1, but not PKCα or SGK1, phosphorylation with
rapamycin. (A) Bar graphs showing number of p-p70S6K1+ and p-4EBP1+ cells in AVF after
rapamycin and control treatment. Top graph, p-p70S6K1: p<0.0001 (ANOVA). *, p<0.0001, day 3;
*, P <0.0001, day 7; *P <0.0001 at day 21 (post hoc); n=4-6. Bottom graph, p-4EBP1: p<0.0001
(ANOVA). *, p<0.0001, day 3; *, p<0.0001, day 7; *, p=0.0010, day 21 (post hoc); n=5-7. (B) Bar
graphs showing number of cells in AVF after control vs rapamycin treatment. Top graph, p-PKCα:
p=0.5130 (ANOVA); n=5. Bottom graph, p-SGK1: p=0.2569 (ANOVA); n=4-5. (C) Representative
Western blot showing p70S6K1 and 4EBP1 phosphorylation after control vs rapamycin
treatment. (D) Graphs showing densitometry measurement of p70S6K1 and p-4EBP1
phosphorylation. p-p70S6K1: t p70S6K1, p<0.0001 (ANOVA). *, p=0.0024, day 7; *, p=0.0024, day
21 (post hoc). n=3. p-4EBP1: t4EBP1, P <0.0001 (ANOVA). *, p=0.0007, day 3; *, p<0.0001, day 7;
*, p=0.0053, day 21 (post hoc). n=3. (E) Graphs showing densitometry measurement of PKCα and
SGK1 phosphorylation. p-PKCα: tPKCα, p=0.9280 (ANOVA); n=3. p-SGK1: tSGK1, p=0.6075
(ANOVA). n=3. (F) Photomicrographs of representative IF for α-actin (green) and p-P70S6K1 (red,
top row) or p-4EBP1 (red, bottom row) in AVF after control or rapamycin treatment; day 7. (G)
Bar graphs showing quantification of dual IF after control or rapamycin treatment, normalized to
sham vessels. p-P70S6K1-α-actin: p<0.0001 (ANOVA); *, p=0.0002, day 3; *, p<0.0001, day 7; *,
p=0.0030, day 21 (post hoc); n=4-5. p-4EBP1-α-actin: p<0.0001 (ANOVA); *, p=0.0378, day 3; *,
p<0.0001, day 7; *, p=0.0109, day 21 (post hoc); n=4-5. (H) Representative photomicrographs of
IF images for CD68 (green) and p-P70S6K1 (red, top row) or p-4EBP1 (red, bottom row) in AVF
after control or rapamycin treatment (day 7). (I) Bar graphs showing quantification of dual IF
after control or rapamycin treatment, normalized to sham vessels. p-P70S6K1-CD68: p<0.0001
(ANOVA); *, p<0.0001, day 3; *, p<0.0001, day 7 (post hoc); n=4-5. p-4EBP1-CD68: p<0.0001
(ANOVA); *, p<0.0001, day 3; *p<0.0001, day 7 (post hoc); n=4-5. Data represent mean ± SEM.
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difference in immunoreactivity of p-PKCα-α-actin dual-positive cells or p-SGK1-α-actin
dual positive cells with rapamycin or control treatments (Supplemental Figure 4F, 4G);
there was also no difference in immunoreactivity of p-PKCα-CD68 dual-positive cells or
p-SGK1-CD68 dual positive cells (Supplemental Figure 4H, 4I). These results show that
rapamycin is associated with less Akt1-mTORC1, but not mTORC2, signaling in SMC and
macrophages, during AVF remodeling.
Since rapamycin inhibits both wall thickness as well as Akt1 and mTORC1
phosphorylation in SMC and macrophages during AVF maturation, we next determined
if the Akt1-mTORC1 axis regulates AVF remodeling. We previously showed that Eph-B4
activation with Ephrin-B2/Fc inhibits Akt1 function in vivo during venous remodeling;36
accordingly, we used Ephrin-B2/Fc to inhibit the Akt1-mTORC1 axis. As expected,
Ephrin-B2/Fc decreased immunoreactivity of p-Akt1-α-actin dual-positive cells; EphrinB2/Fc also diminished p-mTORC1-α-actin dual-positive cells, but not mTORC2-α-actin
dual-positive cells, in the absence of rapamycin (Fig. 5A and B). These data suggest that
diminished Akt1 activity reduces mTORC1 phosphorylation during venous remodeling.
We next examined whether increased Akt1 activity is associated with increased
mTORC1 phosphorylation in vivo during AVF maturation. At the time of AVF creation,
either control vehicle, wild type (WT)-Akt1 adenovirus (Ad), or constitutively active (CA)Akt1 adenovirus was placed in pluronic gel on the adventitia of the AVF; viral vectors
were found within the EC, SMC, and macrophages in the AVF wall, and both viral vectors
had similarly high rates of efficiency (Supplemental Fig. 5A and B). AVF treated with AdCA-Akt1 showed increased venous wall thickening compared to AVF treated with control
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or Ad-WT-Akt1 (Fig. 5C and D). AVF treated with control or Ad-WT-Akt1 showed similar
outward remodeling (Supplemental Figure 5C). Daily IP injections of rapamycin
attenuated the increase in wall thickening in AVF treated with Ad-CA-Akt1 (Fig. 5C and
D). Similarly, there was increased phosphorylation of Akt1 and mTORC1 in AVF treated
with Ad-CA-Akt1, compared to those treated with Ad-WT-Akt1 or control, and
rapamycin attenuated phosphorylation of mTORC1, but not Akt1, in AVF treated with
CA-Akt1 (Fig. 5E and F). In mice treated with rapamycin, there was no sign of clinical
toxicity or significant differences in weight change at day 21 compared to the control
group (Supplemental Figure 5D).
Since rapamycin is associated with reduced mTORC1 phosphorylation in the wall
of the remodeling AVF (Fig. 3C, 3D; Fig. 5E, 5F), we next determined whether the
inhibitory effects of rapamycin were present in either SMC or macrophages. As
expected, there was increased immunoreactivity of p-Akt1-α-actin dual-positive cells
and p-mTORC1-α-actin dual-positive cells in AVF treated with Ad-CA-Akt1 compared to
control or Ad-WT-Akt1. Rapamycin reduced the immunoreactivity of p-mTORC1-α-actin
dual-positive cells, but not p-Akt1-α-actin dual-positive cells, in the AVF treated with AdCA-Akt1 (Fig. 5G; Supplemental Figure 5E). Similarly, rapamycin reduced the
immunoreactivity of p-mTORC1-CD68 dual-positive cells, but not p-Akt1-CD68 dualpositive cells, in the AVF treated with Ad-CA-Akt1 (Fig. 5H; Supplemental Figure 5F).
These results suggest that rapamycin inhibits mTORC1 signaling in both SMC and
macrophages during AVF remodeling.
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Figure 5. Rapamycin inhibits mTORC1 phosphorylation during venous remodeling. (A) Photomicrographs of
representative dual p-Akt1-α-actin (top), p-mTORC1-α-actin (middle) and p-mTORC2-α-actin (bottom) IF in
control or Ephrin-B2/Fc treated mice AVF (day 21). Scale bar, 25μm. L, lumen. (B) Bar graphs showing
quantification of dual p-Akt1-α-actin, p-mTORC1-α-actin, and p-mTORC2-α-actin IF after control or Ephrin-B2/Fc
treatment. p-Akt1-α-actin: *, p=0.0027 (t-test). p-mTORC1-α-actin: *, p<0.0001 (t-test). p-mTORC2-αactin, p=0.8342 (t-test). n=4-5. (C) Photomicrographs showing representative AVF wall thickness in mice treated
with control, Ad-WT-Akt1, Ad-CA-Akt1, and Ad-CA-Akt1 with daily 250 μg IP rapamycin injection (day 21).
Arrowheads denote vessel wall thickness. Scale bar, 25 µm. (D) Bar graph showing AVF wall thickness in mice
treated with pluronic gel containing control, WT-Akt1, constitutively active (CA-) Akt1, and CA-Akt1 with 250 μg
rapamycin (day 21), p<0.0001 (ANOVA); control vs WT-Akt1: p >0.9999; control vs CA-Akt1: *, p<0.0001; Control
vs. CA-Akt1+Rapa: p=0.0789; WT-Akt1 vs. CA-Akt1: *, p<0.0001; WT-Akt1 vs. CA-Akt1+Rapa: p=0.0944; CA-Akt1
vs. CA-Akt1+Rapa: *, p<0.0001 (post-hoc). n=4-5. (E) Representative Western blot showing expression level of
Akt1, p-Akt1, mTORC1 and p-mTORC1 in AVF treated with control, Ad-WT-Akt1, Ad-CA-Akt1, and Ad-CA-Akt1
with rapamycin. (F) Graphs with densitometry measurement of Akt1 and mTORC1 phosphorylation. p-Akt1: t
Akt1: p=0.0015 (ANOVA); Control vs. WT-Akt1: p=0.5435; Control vs. CA-Akt1: *, p=0.0066; Control vs. CAAkt1+Rapa: *, p=0.0019; WT-Akt1 vs. CA-Akt1: *, p=0.0147; WT-Akt1 vs. CA-Akt1+Rapa: *, p=0.0035; CA-Akt1
vs. CA-Akt1+Rapa: p=0.1536 (post hoc); n=3. p-mTORC1: tmTORC1, P =0.0025 (ANOVA). Control vs. WT-Akt1:
p=0.8142; Control vs. CA-Akt1: *, p=0.0076; Control vs. CA-Akt1+Rapa: p=0.1209; WT-Akt1 vs. CA-Akt1: *,
p=0.0125; WT-Akt1 vs. CA-Akt1+Rapa: p=0.0566; CA-Akt1 vs. CA-Akt1+Rapa: *, p=0.0019 (post hoc). n=3. (G)
Bar graphs showing quantification of dual IF after delivery of control, Ad-WT-Akt1, Ad-CA-Akt1, and Ad-CAAkt1+rapamycin. p-Akt1-α-actin: p<0.0001 (ANOVA); control vs. CA-Akt1: *, p=0.0001; control vs. CAAkt1+Rapa: p=0.0015; WT-Akt1 vs. CA-Akt1: *, p=0.0003; WT-Akt1 vs. CA-Akt1+Rapa: p=0.0033 (post hoc). n=45. p-mTORC1-α-actin: p<0.0001 (ANOVA); control vs. CA-Akt1: *, p=0.0007; WT-Akt1 vs. CA-Akt1: p=0.0013; CAAkt1 vs. CA-Akt1+Rapa: **p<0.0001 (post hoc); n=4-5. (H) Bar graphs showing quantification of dual IF after
local delivery of control, WT-Akt1, constitutively active CA-Akt1, and CA-Akt1 with rapamycin. p-Akt1-CD68:
p=0.4265 (ANOVA); control vs. CA-Akt1: *, p=0.0041; control vs. CA-Akt1+Rapa: p=0.0003; WT-Akt1 vs. CA-Akt1:
p=0.0214; WT-Akt1 vs. CA-Akt1+Rapa: *, p=0.0013 (post hoc); n=4-5. p-mTORC1-CD68: p=0.4662 (ANOVA).
control vs. CA-Akt1: *, p=0.0422; control vs. CA-Akt1+Rapa: p=0.0025; WT-Akt1 vs. CA-Akt1: p=0.0036; WT-Akt1
vs. CA-Akt1+Rapa: p=0.0287; CA-Akt1 vs. CA-Akt1+Rapa: **p<0.0001 (post hoc); n=4-5. Data are mean ± SEM.
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4.4. Macrophage depletion is associated with reduced AVF wall thickness and patency
We have previously shown that M2-type macrophages play a role during venous
remodeling such as occurs during vein graft adaptation54 and AVF maturation;15 delivery
of MCP-1 to the AVF adventitia increased M2-type macrophages and increased AVF wall
thickness.15 Since our data suggest that rapamycin has an effect on macrophage
proliferation (Fig. 1), M1 and M2 marker expression (Fig. 2), and Akt1-mTORC1 signaling
(Fig. 3-5), we next examined whether depletion of macrophages would improve AVF
patency. After IP injections of clodronate-containing liposomes, there were significantly
reduced numbers of CD68 immunoreactive cells in the AVF wall (Supplemental Figure
6A). Macrophage depletion was associated with reduced wall thickening that was
characterized by fewer α-actin immunoreactive cells (day 21; Fig. 6A and B). There was
also reduced immunoreactivity of p-Akt1-α-actin dual-positive cells and p-mTORC1-αactin dual-positive cells, but no change in p-mTORC2-α-actin dual-positive cells, in
macrophage-depleted AVF compared to control (Fig. 6C and D). Clodronate increased
the number of apoptotic macrophages but had no effect on EC or SMC apoptosis (Fig. 6E
and F); there was no compensatory increase in proliferation in any cell type (Fig. 6G and
H). At day 7, clodronate-treated AVF showed reduced immunoreactivity of CD68-iNOS,
CD68-TNF-a, CD68-IL-10 and CD68-CD206 dual-positive cells in the adventitia compared
with control AVF (Supplemental Figure 6B). However, at day 21, there was little
immunoreactivity of CD68-iNOS dual-positive cells or CD68-TNF-a dual-positive cells in
either control AVF or clodronate-treated AVF; interestingly, control AVF had some
immunoreactivity of CD68-IL-10 dual-positive cells and CD68-CD206 dual-positive cells
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Figure 6. Macrophage depletion is associated with reduced AVF wall thickness and patency. (A)
Representative photomicrographs showing AVF wall thickness and number of α-actin+ cells in mice treated
with clodronate vs. control (day 21). Scale bar, 25 µm. L, lumen (B) Bar graphs showing AVF wall thickness
(left) and number of α-actin+ cells (right) in AVF after control or clodronate treatment; *p=0.0005 (t test);
n=5. α-actin+ cell number: *p<0.0001 (t test); n=5. (C) Representative photomicrographs showing dual IF
for a-actin (green) and p-Akt1 (red, first row), p-mTORC1 (red, second row) or p-mTORC2 (red, third row) in
AVF after control or clodronate treatment (day 21). (D) Bar graph showing quantification of dual IF in AVF
after control or clodronate treatment. p-Akt1-α-actin: *, p<0.0001 (t test); n=5. p-mTORC1-α-actin: *,
p=0.0011 (t test); n=5. p-mTORC2-α-actin: p=0.5549 (t test); n=5. (E) Photomicrographs showing
representative IF of cleaved caspase-3 (red) merged with ICAM, α-actin or CD68 (green), and DAPI (blue) in
AVF of control or clodronate treated mice (day 7); L, lumen; scale bar, 25 μm. White arrowheads indicate
merged signal. (F) Bar graphs showing percentage of dual positive cells (day 21). Cleaved caspase-3-ICAM:
p>0.9999 (t test); n=4-5. Cleaved caspase-3-α-actin: p=0.9315 (t test). n=4-5. Cleaved caspase-3-CD68:
*p=0.0027 (t test). n= 4-5.(G) Photomicrographs showing representative IF of PCNA (red) merged with
ICAM, α-actin or CD68 (green), and DAPI (blue) in AVF of control or clodronate treated mice (day 7); L,
lumen; scale bar, 25 μm. White arrowheads indicate merged signal. (H) Bar graph showing percentage of
dual positive cells (day 21). PCNA-ICAM positive cells: p=0.8139 (t test); PCNA-α-actin: *, P =0.0035 (t test);
PCNA-CD68: p=0.8547 (t test). n=4-5. (I) Representative photomicrographs showing dual IF for CD68 (red)
and iNOS (green, top row), TNF-a (green, second row), IL-10 (green, third row) or CD206 (green, bottom
row) in AVF after control or clodronate treatment; day 21. Scale bar, 25 μm. L, lumen. (J) Bar graphs
showing quantification of dual IF after control or clodronate treatment (day 21). CD68-iNOS: p=0.7311 (t
test). CD68-TNF-a: p<0.8422 (t test). CD68-IL-10: p<0.0001 (t test). CD68-CD206: p=0.0006 (t test). n=5. (K)
Line graph showing AVF patency rate in mice treated with control or clodronate IP injections. *P = 0.
0.0372 (Log-rank), n=6-7 in each arm.
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that were not observed with clodronate treatment (Fig. 6I and J). Because macrophage
depletion was associated with reduced AVF wall thickness, we next assessed whether
the reduced number of macrophages was also associated with altered AVF patency.
Macrophage depletion significantly reduced the AVF patency by day 28 (Fig. 6K). These
data are consistent with clodronate depletion of both M1- and M2-type macrophages
during AVF maturation and suggest a mechanistic role for macrophages during AVF
adaptive remodeling.

4.5. Rapamycin treatment is associated with reduced AVF wall thickness but increased
AVF patency
The mouse AVF model is characterized by increased wall thickness and dilation
between days 0 and 28, mimicking human AVF maturation; however, between days 28
and 42 there is increased neointimal hyperplasia and loss of patency in approximately
1/3 of mice, mimicking human AVF late failure.42 Since rapamycin treatment was
associated with reduced AVF wall thickness and attenuated SMC and macrophage
proliferation (Fig. 1), we determined the effects of rapamycin on AVF patency; daily
rapamycin or control vehicle injection was continued up to postoperative day 42. In
mice treated with rapamycin daily, there was no sign of clinical toxicity or significant
differences in weight change compared to control mice (Supplemental Figure 7A); there
was also no difference in the technical success rate of AVF creation in rapamycin treated
mice compared to control mice (Supplemental Figure 7B). Rapamycin-treated mice
showed improved AVF patency by day 42 (Fig. 7A); there was no significant difference in
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AVF patency if rapamycin was delivered directly to the adventitia in a single dose at the
time of AVF creation (Supplemental Figure 7B). Mice treated with IP injections of
rapamycin had AVF that showed less thickening but a similar rate of dilation compared
to control mice (Fig. 7B-D).
At day 42, rapamycin-treated AVF showed fewer number of α-actin
immunoreactive cells, with no change in the number of CD68 immunoreactive cells,
compared with control AVF (Fig. 7E and F). AVF of rapamycin treated mice showed
reduced immunoreactivity of α-actin-mTORC-1 dual-positive cells without any change in
immunoreactivity of α-actin-p-Akt1 dual-positive cells or α-actin-p-mTORC2 dualpositive cells (Fig. 7G and H). However, AVF of rapamycin treated mice had similar
immunoreactivity of p-Akt1-CD68 dual-positive cells, p-mTORC1-CD68 dual-positive cells
and p-mTORC2-CD68 dual-positive cells compared to control (Fig. 7I and J). In toto,
these data suggest that rapamycin has sustained inhibition of mTORC1 activity in SMC,
reducing wall thickness and improving AVF patency.

4.6. Rapamycin enhances early AVF remodeling to improve patency
To determine whether the increased patency rate observed after rapamycin
treatment is due to enhancement of AVF remodeling during the early maturation phase
or due to reduced neointimal hyperplasia during later remodeling, rapamycin treatment
was given either only from day 1-21 (early rapamycin) or only from day 22-42 (late
rapamycin); control AVF received only vehicle injections from day 1-42. Compared to
control mice, mice treated with early rapamycin treatment had a trend towards
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Figure 7. Rapamycin treatment is associated with reduced AVF wall thickness but increased
AVF patency. (A) Line graph showing AVF patency rate in mice treated with control vs rapamycin
IP injections. *P = 0.0495 (Log-rank), n=13-14 in each arm. (B) Representative photomicrographs
showing AVF wall thickness in mice treated with control or rapamycin (day 42). Arrowheads
denote wall thickness. Scale bar, 25μm. L, lumen. (C) Bar graph showing AVF wall thickness in
after control or rapamycin treatment (Day 42); *p<0.0001 (t test). n=5. (D) Line graph showing
relative AVF diameter in mice treated with control or rapamycin, normalized to day 0; p=0.2603
(ANOVA); n=6-8. (E) Photomicrographs of representative IF of α-actin+ (top row) and CD68+ cells
(bottom row) in control or rapamycin treated mice AVF (day 42). (F) Bar graphs quantifying
number of α-actin+ (left) and CD68+ cells (right) in AVF after control or rapamycin treatment; αactin: *p<0.0001 (t-test); CD68: p=0.2643 (t test); day 42. n=5. (G) Photomicrographs of
representative dual IF of a-actin (green) and p-Akt1 (red, first row), p-mTORC1 (red, second row)
or p-mTORC2 (red, third row) in AVF after control or rapamycin treatment (day 42). (H) Bar
graphs showing quantification of dual IF in AVF after control or rapamycin treatment (day 42). pAkt1-α-actin: p=0.8126 (t test); p-mTORC1-α-actin: *, p=0.0026 (t test). p-mTORC2-α-actin:
p=0.3206 (t test); n=5. (I) Photomicrographs of representative dual IF for CD68 (green) and pAkt1 (red, first row), p-mTORC1 (red, second row) or p-mTORC2 (red, third row) in AVF after
control or rapamycin treatment (day 42). (J) Bar graphs showing quantification of dual IF in AVF
after control or rapamycin treatment (Day 42). p-Akt1-CD68: p=0.5195 (t test). p-mTORC1-CD68:
p=0.4453 (t test). p-mTORC2-CD68: p=0.6633 (t test); n=5.
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improved AVF patency by day 42; however, compared to control mice, there was no
significant improvement in AVF patency with late rapamycin treatment (Fig. 8A). Mice
treated with early rapamycin, but not late rapamycin, had AVF that showed reduced
thickening, compared to control mice (Fig. 8B and C). Mice treated with early rapamycin
and late rapamycin had a similar rate of dilation compared to control mice (Fig. 8D).
At day 42, AVF treated with early rapamycin, but not AVF treated with late
rapamycin, showed fewer number of α-actin immunoreactive cells, compared to control
AVF (Fig. 8E and F). However, AVF treated with control, early rapamycin or late
rapamycin showed no difference in the number of CD68 immunoreactive cells (Fig. 8E
and F). AVF treated with control, early rapamycin or late rapamycin also showed similar
immunoreactivity of α-actin-p-Akt1 dual-positive cells (Fig. 8G and H). AVF treated with
late rapamycin, but not AVF treated with early rapamycin, had reduced
immunoreactivity of α-actin-p-mTORC1 dual-positive cells compared to control (Fig. 8G
and H). AVF treated with control, early rapamycin, or late rapamycin had similar
immunoreactivity of p-Akt1-CD68 dual-positive cells and p-mTORC1-CD68 dual-positive
cells (Fig. 8I and J). These data suggest that rapamycin improves AVF patency by
enhancing AVF remodeling during the early phase of maturation, whereas rapamycin
treatment only during later remodeling does not improve patency or reduce wall
thickening.
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Figure 8. Rapamycin enhanced early AVF remodeling to improve patency. (A) Line graph showing AVF
patency rate in mice treated with control, early vs late rapamycin. Control vs early rapamycin: P=0.0591
(Log-rank); control vs late rapamycin: P=0.812 (Log-rank); n=5-6 in each group. (B) Representative
photomicrographs showing AVF thickness in mice treated with control, early rapamycin or late
rapamycin (day 42). Arrowheads denote wall thickness. (C) Bar graph showing AVF wall thickness in
after control, early rapamycin or late rapamycin treatment (Day 42); p<0.0001 (ANOVA); control vs
early rapamycin: p<0.0001 (ANOVA); n=5. (D) Line graph showing relative AVF diameter in mice treated
with control, early rapamycin or late rapamycin, normalized to day 0; p=0.6767 (ANOVA); n=5-6. (E)
Photomicrographs of representative IF of α-actin+ (top row) and CD68+ cells (bottom row) in control,
early or late rapamycin treated AVF (day 42). (F) Bar graphs quantifying number of α-actin+ and CD68+
cells in AVF after control, early rapamycin or late rapamycin treatment; α-actin: p<0.0001 (ANOVA); *,
p<0.0001, control vs early rapamycin; CD68: p=0.0813 (ANOVA); day 42. n=4-5. (G) Photomicrographs
of representative dual IF of a-actin (green) and p-Akt1 (red, first row) or p-mTORC1 (red, second row)
in AVF after control, early or late rapamycin treatment (day 42). (H) Bar graphs showing quantification
of dual IF in AVF after control, early rapamycin or late rapamycin treatment (day 42); p-Akt1-α-actin:
p=0.6067 (ANOVA); p-mTORC1-α-actin: *, p=0.0003 (ANOVA); control vs late rapamycin: p=0.009; n=5.
(I) Photomicrographs of representative dual IF for CD68 (green) and p-Akt1 (red) or p-mTORC1 (red) in
AVF after control, early rapamycin or late rapamycin treatment (day 42). (J) Bar graphs showing
quantification of dual IF in AVF after control, early rapamycin or late rapamycin treatment (Day 42). pAkt1-CD68: p=0.4474 (ANOVA); p-mTORC1-CD68: p=0.181 (ANOVA); n=5.
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DISCUSSION
This study shows that rapamycin reduces wall thickening and early inflammation
in AVF as well as proliferation in SMC and macrophages (Fig. 1), suppressing both M1
and M2 macrophage subtypes (Fig. 2). Rapamycin also inhibits Akt1-mTORC1
phosphorylation and downstream signaling in both SMC and macrophages during early
AVF remodeling (Fig. 3 and 4). Macrophage depletion with clodronate reduces wall
thickening but is accompanied by reduced AVF patency with reduced numbers of M1and M2-type macrophages (Fig. 6). However, rapamycin leads to persistently reduced
AVF wall thickening and improved patency by enhancing AVF remodeling during the
early phase of remodeling (Fig. 7 and 8). These results suggest that rapamycin improves
AVF remodeling and long-term patency by reducing inflammation and cell proliferation
during early maturation; in addition, macrophages are necessary for adaptive venous
remodeling.
Our primary finding is that rapamycin improves AVF patency while reducing wall
thickening during the early phase of maturation, with no effect on AVF dilation. Given
the need for therapies that improve vascular access patency, rapamycin and other
antiproliferative agents are currently being investigated in clinical studies. A recent
clinical trial studied a rapamycin-eluting collagen membrane in 12 patients and showed
minimal toxicity, and 1-year primary patency rate of 76% with the treatment,
highlighting a significant improvement in AVF matruation.55 There are currently 2 clinical
trials investigating the use of rapamycin to improve AVF patency. In the ACCESS trial
(NCT02513303),56 patients in the treatment group receive a single dose of rapamycin
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delivered locally, via collagen implants, to the vessel wall at the time of AVF creation. In
the SAVE trial (NCT01595841),57 patients requiring angioplasty to treat AVF failure are
randomized to receive either rapamycin or placebo. Although these trials are still in
progress, there are no pre-clinical studies examining the effects of rapamycin on AVF
patency. Our data suggests that rapamycin treatment initiated during early maturation
reduces both SMC and macrophages in the AVF wall (Fig. 1, 7 and 8), contributing to
improved AVF patency, and support the hypothesis of the ACCESS trial. It is possible that
differences between our mouse model and human AVF are important; however, the
mouse model recapitulates human AVF maturation as well as failure rates, suggesting its
utility in understanding human physiology.42,43 Moreover, mTOR plays a central role in
regulating metabolic cell processes, including protein and lipid
synthesis, and autophagy. Chronic mTORC1 inhibition has been associated with muscle
atrophy, reduced adipogenesis, decreased pancreatic b-cell proliferation and increased
ketogenesis;58 however, despite these potential side effects associated inhibition of
mTORC1, the daily 1.4-1.5 µg/cm2 dose of rapamycin used in our study did not affect
AVF maturation or cause any clinical toxicity.
Our data show that during early AVF remodeling, rapamycin treatment is
associated with reduced SMC proliferation and mTORC1 signaling but has no effect on
proliferation and mTOR signaling in EC (Fig. 1 and 3). These results are consistent with
our previous work showing that selective knockdown of Akt1 from SMC, but not EC,
abolishes AVF remodeling,36 and are also in agreement with the long-established role of
SMC during vascular remodeling. There may be a dual function of mature SMC in AVF,
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with differentiated SMC contributing to medial wall thickening and resultant venous
maturation, and dedifferentiated SMC contributing to detrimental neointimal
hyperplasia.48 It has been suggested that neointimal hyperplasia and the resulting
thrombosis are the major pathological etiologies of AVF failure.59 Rapamycin most likely
reduces the inflammation that causes SMC proliferation in AVF, but not SMC
proliferation directly,60 as shown by its lack of effect on SMC number when given during
late remodeling (Fig. 8). Although rapamycin treatment during late AVF remodeling
reduces mTORC1 signaling in SMC, it does not improve patency or reduce wall
thickening (Fig. 8). This observation confirms that the increased patency rate with
rapamycin treatment is due to enhancement of AVF remodeling during the early
maturation phase when inflammation is most significant (Fig. 1 and 2). The exact
implications of improved patency with a thinner wall remain to be determined; wall
thickening is required for AVF maturation, but uncontrolled pathologic remodeling leads
to AVF failure.3,4 Our data suggests that rapamycin may allow an optimal amount of
initial outward remodeling, but appears to prevent the excessive wall thickening and
inward remodeling that can lead to AVF failure.
AVF creation is associated with local inflammation9 and this inflammatory
response involves the recruitment of macrophages, lymphocytes, and upregulation of
cytokines such as IL-6 and TNF-a, all of which are associated with fistula failure.9,50,61
There is mounting evidence that mTORC1-mediated signaling regulates both adaptive
and innate immune cell function,62-64 and more specifically, rapamycin attenuates the
inflammatory response following vascular injury, with secondary effects on SMC and EC
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proliferation.65,66 Similarly, we observed that rapamycin treatment is associated with
reduced number and proliferation of macrophages (Fig. 1) as well as attenuated Akt1mTORC1 signaling in macrophages during the early maturation phase (Fig. 3). Our data
also shows that following macrophage depletion, SMC proliferation decreases.
Inflammatory cytokines may directly stimulate SMC proliferation and contribute to wall
thickening,67-69 and Akt activation may promote vascular SMC hypertrophy, leading to
formation of neointimal hyperplasia.70 Reducing macrophage accumulation decreases
SMC hyperplasia in vivo, suggesting, as we observe in our AVF model, that macrophages
play an important role in determining SMC activity during vascular remodeling.67
Although the exact role of specific macrophage subtypes during AVF maturation
remains unknown, M1 macrophages accumulate during the early maturation phase of
venous remodeling, with subsequent increased numbers of M2 macrophages during
later maturation phases (Fig. 6J).49 Thus, limiting rapamycin delivery to the very early
phase of maturation to inhibit M1-type macrophage activity appears to result in similar
or even more improved AVF remodeling (Fig. 8). We have previously shown that CD44
promotes accumulation of M2-type macrophages, ECM deposition, and inflammation
resulting in enhanced AVF maturation.15 We have also shown that M2-type macrophage
function may be an important mechanism in regulating venous remodeling such as
occurs during vein graft adaptation.54 This study shows that rapamycin attenuates both
M1 and M2 macrophage activity. While inhibition of pro-inflammatory M1 activity might
be advantageous in improving AVF patency, complete diminution of macrophage
function appears to be detrimental to AVF patency, possibly by sustained inhibition of
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the M2-type macrophages (Fig. 6). However, when used to reduce, as opposed to
deplete, both macrophage phenotypes, rapamycin is associated with improved AVF
remodeling and patency (Fig. 7). There are mixed reports of rapamycin affecting M2type macrophage survival and polarizing the phenotype to an M1-like inflammatory
response both in vivo and in vitro71 as well as favoring macrophage polarization toward
an M2 anti-inflammatory response;72 nonetheless, rapamycin treatment is associated
with reduced M1- and M2-type macrophages during venous remodeling.
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Conclusion
In conclusion, rapamycin improves AVF patency and early venous remodeling
while reducing wall thickening and early inflammation. These effects are associated with
reduced Akt1-mTORC1 signaling in macrophages and SMC during the early maturation
phase and sustained reduction in SMC during the late maturation phase. Macrophages
are essential for AVF remodeling and M2 macrophages may have a mechanistic role in
AVF maturation. The mTORC1 pathway is a key regulator of AVF maturation and its
inhibition with rapamycin may be a translational strategy to improve AVF patency.
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Appendix

Supplementary Figure 1. Reduced AVF wall thickness, extracellular matrix deposition, SMC and
macrophages with rapamycin. (A) Bar graphs showing quantification of serum rapamycin
concentration, *P<0.0001 (t test); BUN, p=0.8506 (t test); creatinine, p=0.3830 (t test); hemoglobin,
p=0.8502 (t test); platelet, p=0.1116 (t test); white blood cell, p=0.1763 (t test); lymphocyte, p=0.0977
(t test); neutrophil, p=0.2924 (t test); monocyte, p=0.6748 (t test); weight loss, p=0.5467 (t test) after
control or rapamycin treatment in mice (day7); n=4-5. (B) Top panel: aortocaval fistula in mice
treated with control vs rapamycin; middle panel: retroperitoneal tissue dissected to obtain proximal
control of the aorta and IVC; bottom panel: extracted AVF tied just below the renal veins; arrow
denotes IVC; scale bar, 1 cm. (C) AVF just below the renal veins in mice treated with control vs
rapamycin; *: AVF; AO: aorta; scale bar, 100µm. (D) Photomicrographs showing AVF wall thickness in
mice treated with control vs rapamycin. Scale bar, 25 µm. L, lumen. (E) Line graph showing relative
AVF arterial diameter in mice treated with control or rapamycin; normalized to day 0; p=0.5(ANOVA).
n=5-6. (F) Photomicrographs showing dual immunofluorescence (IF) for ICAM-1 (green) and p-eNOS
(red) in AVF after control or rapamycin treatment; day 3, day 7 and day 21.
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Supplementary Figure 1 (continued). (G) Representative IF photomicrographs showing extracellular
matrix immunoreactivity in control or rapamycin treated groups. Collagen I and III (red) and fibronectin
(green). (H) Representative IF photomicrographs of ICAM-1 (top row), α-actin (middle row) and CD68+
cells (bottom row) in control or rapamycin treated mice AVF. (I) Photomicrographs showing representative
IF of PCNA (red) merged with ICAM, α-actin or CD68 (green), and DAPI (blue) in AVF of control vs
rapamycin treated mice (day 3 and 7); L, lumen; scale bar, 25 μm. (J) Photomicrographs showing
representative IF of cleaved caspase-3 (red) merged with ICAM, α-actin or CD68 (green), and DAPI (blue) in
AVF of control or rapamycin treated mice (day 3 and 7); L, lumen; scale bar, 25 μm.
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Supplementary Figure 2. Reduced M1- and M2-type macrophages with rapamycin. (A)
Representative photomicrographs showing dual IF for CD68 (red) and iNOS (green, top
row), TNF-α (green, bottom row). (B) IL10 (green, top row) or CD206 (green, bottom row)
in AVF after control or rapamycin treatment. (C) Representative IF photomicrographs of
CD45+ cells. Scale bar, 25 µm. L, lumen. (D) Representative IF photomicrographs of
VCAM-1 (top row) and ICAM-1 (bottom row) in the AVF after control or rapamycin
treatment.
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Supplementary Figure 3. Reduced Akt1 and mTORC1 but not mTORC2 phosphorylation with
rapamycin. (A) Representative IF photomicrographs of p-Akt1+ (top), p-mTORC1+ (middle) and
p-mTORC2+ (bottom) cells in control or rapamycin treated mice AVF; sham, day 3 and day 21.
Scale bar, 25μm. L, lumen. (B) Representative photomicrographs showing dual IF for ICAM-1
(green) and p-Akt1 (red, first row) or p-mTORC1 (red, second row) in AVF after control or
rapamycin treatment; sham, day 3, day 7 and day 21. (C) Bar graphs showing quantification of
dual IF after control or rapamycin treatment. p-Akt1-α-actin: p=0.2036 (ANOVA); n=4-5. pmTORC1-ICAM: p=0.4876 (ANOVA); n=4. (D) Representative photomicrographs showing dual IF
for α-actin (red) and p-Akt1 (green, top row), α-actin (green) and p-mTORC1 (red, bottom row),
(E) CD68 (red) and p-Akt1 (green, first row), CD68 (green) p-mTORC1 (red, second row) in AVF
after control or rapamycin treatment; sham, day 3 and day 21.
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Supplementary Figure 4. Reduced p70S6K1 and 4EBP1, but not PKCα or SGK1, phosphorylation with
rapamycin. (A) Photomicrographs of representative IF images of p-p70S6K1+ and p-4EBP1+ cells in control
or rapamycin treated mice AVF. Scale bar, 25μm. L, lumen. (B) Photomicrographs of representative IF
images of p-PKCα+ and p-SGK1+ cells in control or rapamycin treated mice AVF. Scale bar, 25μm. L, lumen.
(C) Representative Western blot showing phosphorylation level of PKCα and SGK1 after control or
rapamycin treatment. (D) Photomicrographs of representative IF images for α-actin (green) and pP70S6K1 (red, top row) or p-4EBP1 (red, bottom row) as well as (E) CD68 (red) and p-P70S6K1 (green, top
row) or p-4EBP1 (green, bottom row) in AVF after control or rapamycin treatment.
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Supplementary Figure 4 (continued). Reduced p70S6K1 and 4EBP1, but not PKCα or SGK1,
phosphorylation with rapamycin. (F) Microphotographs of representative IF images for α-actin
(green) and p-PKCα (red, top row) or p-SGK1 (red, bottom row) in AVF after control or rapamycin
treatment. (G) Bar graphs showing quantification of dual IF after control or rapamycin
treatment, normalized to sham. p-PKCα-α-actin: p=0.6597 (ANOVA); n=4-5. p-SGK1-αactin, p=0.01024 (ANOVA); n=4-5. (H) Photomicrographs of representative IF images for CD68
(green) and p-PKCα (red, top row) or p-SGK1 (red, bottom row) in AVF after control or rapamycin
treatment. (I) Bar graphs showing quantification of dual IF after control or rapamycin treatment,
normalized to sham. p-PKCα-CD68: p=0.3697 (ANOVA). p-SGK1-CD68, p=0.3341 (ANOVA. n=4-5.
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Supplementary Figure 5. Rapamycin inhibits mTORC1 phosphorylation during venous
remodeling. (A) Representative photomicrographs showing dual IF for α-actin, CD68 or ICAM
(green) and HA (red) in AVF after adventitial delivery of control, WT-Akt1, and CA-Akt1; day 21.
Scale bar, 25μm. L, lumen. (B) Bar graphs showing proportion of HA-ICAM+ to total ICAM+, HAα-actin+ to total α-actin+, and HA-CD68+ to total CD68+ cells after adventitial delivery of control,
WT-Akt1, and CA-Akt1; normalized to control. HA-ICAM: p=0.0012 (ANOVA); Control vs. WTAkt1: *, p=0.0136; Control vs. CA-Akt1: **, p=0.0064 (post hoc); n=4. HA-α-actin: p=0.0030
(ANOVA); Control vs. WT-Akt1: *p<0.0001; Control vs. CA-Akt1: **p<0.0001 (post hoc); n=4. HACD68: p=0.0010 (ANOVA); Control vs. WT-Akt1: *p=0.0006, Control vs. CA-Akt1: **p=0.0004
(post hoc); n=4. (D) Bar graphs showing quantification of weight loss, p=0.1926 (t test) after
control or rapamycin treatment in mice (day 21); n=4-5. (C) Line graph showing AVF diameter in
mice treated with control, WT-Akt1-Ad, CA-Akt1-Ad or CA-Akt1-Ad with rapamycin. p=0.1817
(ANOVA). n=4–5. (E) Representative photomicrographs showing dual IF for α-actin (green) and
p-Akt1 (red, top row) or p-mTORC1 (red, bottom row) as well as (F) CD68 (green) and p-Akt1
(red, top row) or p-mTORC1 (red, bottom row) in AVF after local delivery of control, WT-Akt1, CAAkt1, and CA-Akt1 with daily 250 μg IP rapamycin injection (day 21).

49

Supplementary Figure 6. Macrophage depletion is associated with reduced AVF wall thickness
and patency. (A) Representative photomicrographs showing CD68+ immunoreactive cells in mice
treated with control or clodronate. Scale bar, 25μm. L, lumen. Bar graphs showing number of
CD68+ cells in AVF after control or clodronate treatment. *p<0.0001 (t test). n=5. (B)
Representative photomicrographs showing dual IF for CD68 (red) and iNOS (green, top row),
TNF-a (green, second row), IL-10 (green, third row) or CD206 (green, bottom row) in AVF after
control or rapamycin treatment; day 7. Scale bar, 25 μm. L, lumen. Bar graphs showing
quantification of dual IF after control or clodronate treatment (day 7). CD68-iNOS: p=0.01351 (t
test). CD68-TNF-a: p<0.0001 (t test). CD68-IL-10: p<0.0008 (t test). CD68-CD206: p=0.0011 (t
test). n=5.
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Supplementary Figure 7. Rapamycin treatment is associated with reduced AVF wall thickness
but increased AVF patency. (A) Bar graphs showing quantification of weight change, p=0.1977 (t
test) after control or rapamycin treatment in mice (day 42); n=12-13. (B) Technical success rate
of AVF creation in rapamycin treated group (77.8%; 14/18) compared to control (76.5%; 13/17);
P=0.9871 (chi-square). (C) Line graph showing AVF patency rate in mice treated with IP
rapamycin or adventitial delivery of a single dose of rapamycin via pluronic gel. *P = 0.9027 (Logrank), n=6-7 in each arm.

